busulfan has been researched along with Ewing Sarcoma in 29 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS)." | 9.51 | High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. ( Bauer, S; Baumhoer, D; Bernkopf, M; Bhadri, V; Bonar, F; Bovee, J; Brichard, B; Burdach, S; Butterfaß-Bahloul, T; Collaud, S; Cyprova, S; Dhooge, C; Dirksen, U; Egerer, G; Eich, HT; Ek, T; Faldum, A; Gelderblom, H; Hardes, J; Hartmann, W; Hassenpflug, W; Hauser, P; Haveman, L; Hjorth, L; Hong, A; Jürgens, H; Kanerva, J; Kessler, T; Kiss, J; Koch, R; Kruseova, J; Kühne, T; Metzler, M; Paulussen, M; Raciborska, A; Ranft, A; Rascon, J; Reichardt, P; Renard, M; Timmermann, B; van den Berg, H; Vieth, V, 2022) |
| "We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma." | 9.20 | A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. ( Forsyth, S; Michelagnoli, M; Whelan, J, 2015) |
| "This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT)." | 7.88 | Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( Abate, ME; Cammelli, S; Carretta, E; Cesari, M; Ferrari, S; Longhi, A; Paioli, A; Palmerini, E; Picci, P; Piscaglia, F, 2018) |
| "A Ewing sarcoma grown in immunosuppressed mice was eradicated with a single lethal dose of dimethylmyleran (DMM) followed by autologous or syngeneic bone marrow." | 7.66 | Control of a human tumour (Ewing sarcoma) in mice by a single lethal dose of dimethyl-myleran and bone marrow. ( Floersheim, GL; Torhorst, J, 1981) |
| "Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS)." | 5.51 | High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. ( Bauer, S; Baumhoer, D; Bernkopf, M; Bhadri, V; Bonar, F; Bovee, J; Brichard, B; Burdach, S; Butterfaß-Bahloul, T; Collaud, S; Cyprova, S; Dhooge, C; Dirksen, U; Egerer, G; Eich, HT; Ek, T; Faldum, A; Gelderblom, H; Hardes, J; Hartmann, W; Hassenpflug, W; Hauser, P; Haveman, L; Hjorth, L; Hong, A; Jürgens, H; Kanerva, J; Kessler, T; Kiss, J; Koch, R; Kruseova, J; Kühne, T; Metzler, M; Paulussen, M; Raciborska, A; Ranft, A; Rascon, J; Reichardt, P; Renard, M; Timmermann, B; van den Berg, H; Vieth, V, 2022) |
| "Dose-intensive chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide is more effective, less toxic, and shorter in duration for all stages of newly diagnosed Ewing sarcoma than vincristine, ifosfamide, doxorubicin, and etoposide induction and should now be the standard of care for Ewing sarcoma." | 5.51 | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. ( Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J, 2022) |
| "Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord." | 5.33 | Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. ( Cassoni, AM; Galloway, MJ; Rees, JH; Seddon, BM; Whelan, JS, 2005) |
| "We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma." | 5.20 | A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. ( Forsyth, S; Michelagnoli, M; Whelan, J, 2015) |
| "Patients aged ≤40 years with nonmetastatic Ewing sarcoma (ES) received vincristine (V), doxorubicin (A), cyclofosfamide (C), actinomycin (Ac), ifosfamide (I) and etoposide (E) (VACAc-IE regimen) as induction chemotherapy." | 5.15 | Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. ( Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T, 2011) |
| "To improve the prognosis for patients with metastatic Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET) using conventional chemotherapy and consolidation high-dose chemotherapy (HDCT) containing busulfan and melphalan." | 5.12 | Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. ( Desfachelles, AS; Lejars, O; Michon, J; Oberlin, O; Philip, T; Plantaz, D; Plouvier, E; Rey, A; Rubie, H; Schmitt, C; Terrier, P, 2006) |
| "This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT)." | 3.88 | Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( Abate, ME; Cammelli, S; Carretta, E; Cesari, M; Ferrari, S; Longhi, A; Paioli, A; Palmerini, E; Picci, P; Piscaglia, F, 2018) |
| "Post-relapse survival (PRS) was evaluated in patients with Ewing sarcoma (EWS) enrolled in chemotherapy protocols based on the use of high-dose chemotherapy with busulfan and melfalan (HDT) as a first-line consolidation treatment in high-risk patients." | 3.81 | Post-relapse survival in patients with Ewing sarcoma. ( Abate, ME; Brach del Prever, A; Cammelli, S; DiGirolamo, S; Eriksson, M; Fagioli, F; Ferrari, S; Hall, KS; Luksch, R; Paioli, A; Podda, M; Prete, A; Tamburini, A; Tienghi, A, 2015) |
| "To evaluate the potential of diffusion-weighted imaging (DWI) for monitoring dose-dependent tumor response in a mouse-xenograft model of Ewing sarcoma after administration of treosulfan in different dosages." | 3.75 | Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. ( Elverfeldt, DV; Juettner, E; Kontny, U; Reichardt, W; Uhl, M, 2009) |
| " As little data are available about the in-vitro toxicity of busulfan and treosulfan especially on pediatric tumor cell lines, we compared the cytotoxicity of treosulfan and busulfan on four Ewing tumor, four neuroblastoma, two osteosarcoma and two leukemia cell lines in vitro." | 3.73 | Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. ( Boos, J; Bremer, A; Dirksen, U; Jürgens, H; Lanvers-Kaminsky, C, 2006) |
| "A Ewing sarcoma grown in immunosuppressed mice was eradicated with a single lethal dose of dimethylmyleran (DMM) followed by autologous or syngeneic bone marrow." | 3.66 | Control of a human tumour (Ewing sarcoma) in mice by a single lethal dose of dimethyl-myleran and bone marrow. ( Floersheim, GL; Torhorst, J, 1981) |
| " Whenever one patient at one dosage level showed a grade III or grade IV reversible toxicity, additional patients were admitted (one by one) up to a maximum number of 6." | 2.69 | Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors. ( Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A, 1999) |
| "Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord." | 1.33 | Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. ( Cassoni, AM; Galloway, MJ; Rees, JH; Seddon, BM; Whelan, JS, 2005) |
| "Eighteen patients with poor risk Ewing's sarcoma (including 11 patients with metastatic disease at presentation) received consolidation therapy of busulphan and melphalan with autologous stem cell rescue." | 1.30 | High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. ( Ashley, S; Atra, A; Calvagna, V; Pinkerton, CR; Shankar, AG; Shepherd, V; Souhami, RL; Whelan, JS, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 6 (20.69) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 8 (27.59) | 24.3611 |
| 2020's | 5 (17.24) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, R | 1 |
| Gelderblom, H | 4 |
| Haveman, L | 1 |
| Brichard, B | 1 |
| Jürgens, H | 3 |
| Cyprova, S | 1 |
| van den Berg, H | 1 |
| Hassenpflug, W | 1 |
| Raciborska, A | 2 |
| Ek, T | 1 |
| Baumhoer, D | 1 |
| Egerer, G | 1 |
| Eich, HT | 2 |
| Renard, M | 1 |
| Hauser, P | 1 |
| Burdach, S | 1 |
| Bovee, J | 1 |
| Bonar, F | 1 |
| Reichardt, P | 1 |
| Kruseova, J | 1 |
| Hardes, J | 1 |
| Kühne, T | 1 |
| Kessler, T | 1 |
| Collaud, S | 1 |
| Bernkopf, M | 1 |
| Butterfaß-Bahloul, T | 1 |
| Dhooge, C | 1 |
| Bauer, S | 1 |
| Kiss, J | 1 |
| Paulussen, M | 1 |
| Hong, A | 1 |
| Ranft, A | 2 |
| Timmermann, B | 1 |
| Rascon, J | 1 |
| Vieth, V | 1 |
| Kanerva, J | 1 |
| Faldum, A | 1 |
| Metzler, M | 1 |
| Hartmann, W | 1 |
| Hjorth, L | 1 |
| Bhadri, V | 1 |
| Dirksen, U | 3 |
| Cohen, IJ | 1 |
| Ash, S | 1 |
| Brennan, B | 3 |
| Kirton, L | 2 |
| Marec-Bérard, P | 3 |
| Gaspar, N | 3 |
| Laurence, V | 4 |
| Martín-Broto, J | 3 |
| Sastre, A | 3 |
| Owens, C | 3 |
| Fenwick, N | 3 |
| Strauss, S | 3 |
| Moroz, V | 3 |
| Whelan, J | 4 |
| Wheatley, K | 3 |
| Anderton, J | 1 |
| Kaiser, S | 1 |
| Fernández-Pinto, M | 1 |
| Evans, A | 1 |
| Scobioala, S | 1 |
| Abate, ME | 3 |
| Paioli, A | 2 |
| Cammelli, S | 2 |
| Cesari, M | 1 |
| Longhi, A | 1 |
| Palmerini, E | 1 |
| Ferrari, S | 4 |
| Carretta, E | 1 |
| Picci, P | 3 |
| Piscaglia, F | 1 |
| Michelagnoli, M | 1 |
| Forsyth, S | 1 |
| Luksch, R | 3 |
| Hall, KS | 2 |
| Fagioli, F | 3 |
| Prete, A | 4 |
| Tamburini, A | 3 |
| Tienghi, A | 3 |
| DiGirolamo, S | 1 |
| Podda, M | 2 |
| Eriksson, M | 2 |
| Brach del Prever, A | 2 |
| Dourthe, ME | 1 |
| Ternès, N | 1 |
| Gajda, D | 1 |
| Paci, A | 1 |
| Dufour, C | 1 |
| Benhamou, E | 1 |
| Valteau-Couanet, D | 2 |
| Reichardt, W | 2 |
| Juettner, E | 1 |
| Uhl, M | 2 |
| Elverfeldt, DV | 1 |
| Kontny, U | 2 |
| Bölling, T | 1 |
| Ernst, I | 1 |
| Willich, N | 1 |
| Diaz, MA | 2 |
| Lassaletta, A | 1 |
| Perez, A | 1 |
| Sevilla, J | 1 |
| Madero, L | 2 |
| Gonzalez-Vicent, M | 1 |
| Sundby Hall, K | 1 |
| Wiebe, T | 1 |
| Alvegard, TA | 1 |
| Alberghini, M | 1 |
| Gandola, L | 2 |
| Mercuri, M | 1 |
| Capanna, R | 1 |
| Mapelli, S | 1 |
| Carli, M | 1 |
| Barbieri, E | 2 |
| Bacci, G | 1 |
| Smeland, S | 2 |
| Drabko, K | 1 |
| Bilska, K | 1 |
| Styczynski, J | 1 |
| Ussowicz, M | 1 |
| Choma, M | 1 |
| Wojcik, B | 1 |
| Zaucha-Prazmo, A | 1 |
| Gorczynska, E | 1 |
| Skoczen, S | 1 |
| Wozniak, W | 1 |
| Chybicka, A | 1 |
| Wysocki, M | 1 |
| Gozdzik, J | 1 |
| Kowalczyk, J | 1 |
| Ruggieri, P | 1 |
| Daolio, P | 1 |
| Lindholm, P | 1 |
| Bisogno, G | 1 |
| Grignani, G | 1 |
| Pierga, JY | 1 |
| Barthier, S | 1 |
| Babinet, A | 1 |
| Alapetite, C | 1 |
| Palangié, T | 1 |
| de Pinieux, G | 1 |
| Anract, P | 1 |
| Pouillart, P | 1 |
| Seddon, BM | 1 |
| Cassoni, AM | 1 |
| Galloway, MJ | 1 |
| Rees, JH | 1 |
| Whelan, JS | 3 |
| McTiernan, A | 1 |
| Driver, D | 1 |
| Michelagnoli, MP | 1 |
| Kilby, AM | 1 |
| Lanvers-Kaminsky, C | 1 |
| Bremer, A | 1 |
| Boos, J | 1 |
| Oberlin, O | 1 |
| Rey, A | 1 |
| Desfachelles, AS | 1 |
| Philip, T | 1 |
| Plantaz, D | 1 |
| Schmitt, C | 1 |
| Plouvier, E | 1 |
| Lejars, O | 1 |
| Rubie, H | 1 |
| Terrier, P | 1 |
| Michon, J | 1 |
| Werner, S | 1 |
| Mendoza, A | 1 |
| Hilger, RA | 1 |
| Erlacher, M | 1 |
| Lissat, A | 1 |
| Konanz, C | 1 |
| Niemeyer, CM | 1 |
| Khanna, C | 1 |
| Floersheim, GL | 1 |
| Torhorst, J | 1 |
| Mitchell, PL | 1 |
| Shepherd, VB | 1 |
| Proctor, HM | 1 |
| Dainton, M | 1 |
| Cabral, SD | 1 |
| Pinkerton, CR | 2 |
| Vassal, G | 1 |
| Challine, D | 1 |
| Koscielny, S | 1 |
| Hartmann, O | 1 |
| Deroussent, A | 1 |
| Boland, I | 1 |
| Lemerle, J | 1 |
| Lévi, F | 1 |
| Gouyette, A | 1 |
| Atra, A | 1 |
| Calvagna, V | 1 |
| Shankar, AG | 1 |
| Ashley, S | 1 |
| Shepherd, V | 1 |
| Souhami, RL | 1 |
| Yonemoto, T | 1 |
| Tatezaki, S | 1 |
| Ishii, T | 1 |
| Satoh, T | 1 |
| Pession, A | 1 |
| Locatelli, F | 1 |
| Bella, S | 1 |
| Melchionda, F | 1 |
| Garaventa, A | 1 |
| Burnelli, R | 1 |
| Paolucci, G | 1 |
| Vicent, MG | 1 |
| Hawkins, D | 1 |
| Barnett, T | 1 |
| Bensinger, W | 1 |
| Gooley, T | 1 |
| Sanders, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma[NCT00987636] | Phase 3 | 907 participants (Actual) | Interventional | 2009-10-01 | Completed | ||
| Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse[NCT04758000] | Phase 2 | 67 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893] | 100 participants (Anticipated) | Observational | 2021-06-01 | Recruiting | |||
| A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco[NCT00003081] | Phase 1 | 16 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for busulfan and Ewing Sarcoma
| Article | Year |
|---|---|
Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Thera | 2020 |
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2005 |
9 trials available for busulfan and Ewing Sarcoma
| Article | Year |
|---|---|
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Consolidation Chemother | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; | 2020 |
A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan | 2015 |
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2011 |
Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2006 |
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1999 |
High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Disease | 1999 |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2000 |
18 other studies available for busulfan and Ewing Sarcoma
| Article | Year |
|---|---|
New Approaches Promise to Improve Local Ewing Sarcoma Results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Disease-Free Survival; Hum | 2022 |
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantatio | 2018 |
Post-relapse survival in patients with Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2015 |
Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantatio | 2016 |
Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Line, Tumor; Diffusion Ma | 2009 |
Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Chemotherapy, | 2009 |
High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Melph | 2010 |
Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2012 |
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2012 |
Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Combined Modal | 2005 |
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Busulfa | 2006 |
Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Survival; Humans; Leukemia; Neurob | 2006 |
Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Topics: Animals; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Bisbenzimidazole; Blotting, Weste | 2008 |
Control of a human tumour (Ewing sarcoma) in mice by a single lethal dose of dimethyl-myleran and bone marrow.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Dose-Response Relationship, Drug; Humans; Immunosupp | 1981 |
Peripheral blood stem cells used to augment autologous bone marrow transplantation.
Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; | 1994 |
Chronopharmacology of high-dose busulfan in children.
Topics: Bone Marrow Transplantation; Brain Neoplasms; Busulfan; Child; Child, Preschool; Circadian Rhythm; D | 1993 |
High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 1997 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 1999 |